EGFR and neoplasm: Our previous study demonstrated that the modular structure of the BsAb allows generation of BsAbs with specificity to different tumor antigens [i.e., epidermal growth factor receptor (EGFR)] and actively delivers mPEGylated nanoparticles (e.g., therapeutic agents or image probes) to SW480 (EGFR+) but not SW620 (EGFR-) tumor cells25.